Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the amount of two incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are normally produced naturally by the body in response to food intake. Their function is to help control blood sugar (glucose) levels. It is used to treat type 2 or non-insulin dependent diabetes (NIDDM) in combination with a sulphonyl urea, metformin or a glitazone.
Kimia Biosciences Ltd™ is engaged in manufacturing of bulk drugs addressing to various high potential therapeutic segments and has envisaged high growth plans through infrastructure creation and CMS. Kimia has earmarked significant investment for this over next two years to become one of the major players in the Indian market. Moving forward towards vertical integration we have plans to set up our own FFF facilities for lifestyle segments with international regulatory standards to be able to not only launch itself in ROW but advance markets as well in future times. For More Info: https://www.kimiabiosciences.com/product/vildagliptin |
|
